Zymeworks Common Stock Stock Performance

ZYME Stock  USD 24.11  0.48  2.03%   
The firm maintains a market beta of -0.0816, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Zymeworks Common are expected to decrease at a much lower rate. During the bear market, Zymeworks Common is likely to outperform the market. At this point, Zymeworks Common Stock has a negative expected return of -0.18%. Please make sure to check out Zymeworks Common's skewness, and the relationship between the value at risk and day median price , to decide if Zymeworks Common Stock performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Zymeworks Common Stock has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's primary indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders. ...more

Actual Historical Performance (%)

One Day Return
2.78
Five Day Return
3.82
Year To Date Return
(11.23)
Ten Year Return
81.77
All Time Return
81.77
1
Zymeworks Rating Increased to Strong-Buy at Citizens Jmp
12/05/2025
2
Disposition of 100000 shares by Kenneth Galbraith of Zymeworks Common subject to Rule 16b-3
12/22/2025
3
Zymeworks Trading Down 6.1 percent Heres What Happened
01/05/2026
4
Jeffrey Smith Sells 10,538 Shares of Zymeworks Stock
01/06/2026
5
Assessing Zymeworks Valuation After Positive Phase 3 Ziihera Trial Results
01/07/2026
6
Insider Trading
01/09/2026
7
Zymeworks announce key mangement changes
01/12/2026
8
Zymeworks CEO Sells 689,712.08 in Stock
01/13/2026
9
A Look At Zymeworks Valuation After Positive HERIZON GEA 01 Trial Results And Royalty Milestone Potential
01/16/2026
10
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
02/12/2026
11
How Positive Zanidatamab Phase 3 Data And Buyback Plans At Zymeworks Have Changed Its Investment Story
02/24/2026
Begin Period Cash Flow157.6 M
Total Cashflows From Investing Activities38.8 M

Zymeworks Common Relative Risk vs. Return Landscape

If you would invest  2,671  in Zymeworks Common Stock on November 27, 2025 and sell it today you would lose (308.00) from holding Zymeworks Common Stock or give up 11.53% of portfolio value over 90 days. Zymeworks Common Stock is currently does not generate positive expected returns and assumes 2.4383% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than Zymeworks, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Zymeworks Common is expected to under-perform the market. In addition to that, the company is 3.19 times more volatile than its market benchmark. It trades about -0.07 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of volatility.

Zymeworks Common Target Price Odds to finish over Current Price

The tendency of Zymeworks Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 24.11 90 days 24.11 
about 59.58
Based on a normal probability distribution, the odds of Zymeworks Common to move above the current price in 90 days from now is about 59.58 (This Zymeworks Common Stock probability density function shows the probability of Zymeworks Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Zymeworks Common Stock has a beta of -0.0816. This usually means as returns on the benchmark increase, returns on holding Zymeworks Common are expected to decrease at a much lower rate. During a bear market, however, Zymeworks Common Stock is likely to outperform the market. Additionally Zymeworks Common Stock has an alpha of 0.0727, implying that it can generate a 0.0727 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Zymeworks Common Price Density   
       Price  

Predictive Modules for Zymeworks Common

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Zymeworks Common Stock. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
21.2223.6626.10
Details
Intrinsic
Valuation
LowRealHigh
21.2728.4130.85
Details
Naive
Forecast
LowNextHigh
20.5122.9425.38
Details
10 Analysts
Consensus
LowTargetHigh
33.1836.4640.47
Details

Zymeworks Common Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Zymeworks Common is not an exception. The market had few large corrections towards the Zymeworks Common's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Zymeworks Common Stock, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Zymeworks Common within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.07
β
Beta against Dow Jones-0.08
σ
Overall volatility
1.65
Ir
Information ratio -0.0099

Zymeworks Common Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Zymeworks Common for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Zymeworks Common Stock can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Zymeworks Common generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 76.3 M. Net Loss for the year was (122.69 M) with loss before overhead, payroll, taxes, and interest of (8.35 M).
Zymeworks Common Stock currently holds about 241.83 M in cash with (110.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.18.
Over 97.0% of the company outstanding shares are owned by institutional investors
Latest headline from simplywall.st: How Positive Zanidatamab Phase 3 Data And Buyback Plans At Zymeworks Have Changed Its Investment Story

Zymeworks Common Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Zymeworks Stock often depends not only on the future outlook of the current and potential Zymeworks Common's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Zymeworks Common's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding75.9 M
Cash And Short Term Investments225.8 M

Zymeworks Common Fundamentals Growth

Zymeworks Stock prices reflect investors' perceptions of the future prospects and financial health of Zymeworks Common, and Zymeworks Common fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Zymeworks Stock performance.

About Zymeworks Common Performance

By analyzing Zymeworks Common's fundamental ratios, stakeholders can gain valuable insights into Zymeworks Common's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Zymeworks Common has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Zymeworks Common has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.25)(0.26)
Return On Capital Employed(0.33)(0.35)
Return On Assets(0.24)(0.25)
Return On Equity(0.33)(0.34)

Things to note about Zymeworks Common Stock performance evaluation

Checking the ongoing alerts about Zymeworks Common for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Zymeworks Common Stock help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Zymeworks Common generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 76.3 M. Net Loss for the year was (122.69 M) with loss before overhead, payroll, taxes, and interest of (8.35 M).
Zymeworks Common Stock currently holds about 241.83 M in cash with (110.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.18.
Over 97.0% of the company outstanding shares are owned by institutional investors
Latest headline from simplywall.st: How Positive Zanidatamab Phase 3 Data And Buyback Plans At Zymeworks Have Changed Its Investment Story
Evaluating Zymeworks Common's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Zymeworks Common's stock performance include:
  • Analyzing Zymeworks Common's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Zymeworks Common's stock is overvalued or undervalued compared to its peers.
  • Examining Zymeworks Common's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Zymeworks Common's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Zymeworks Common's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Zymeworks Common's stock. These opinions can provide insight into Zymeworks Common's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Zymeworks Common's stock performance is not an exact science, and many factors can impact Zymeworks Common's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Zymeworks Stock analysis

When running Zymeworks Common's price analysis, check to measure Zymeworks Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zymeworks Common is operating at the current time. Most of Zymeworks Common's value examination focuses on studying past and present price action to predict the probability of Zymeworks Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zymeworks Common's price. Additionally, you may evaluate how the addition of Zymeworks Common to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments